BioSpace News Archive

After a serious injury, the leading cause of death is loss of blood. Major trauma victims who receive transfusions of packed blood 22 days old or older may face increased risk of death within 24 hours, according to a new study in Annals of Emergency Medicine.

Generex Biotechnology Corporation (OTCMKTS:GNBT) announced today the appointment of Anthony J. Dolisi as Generex Chief Commercial Officer and Michelle Starr as Generex Chief Marketing Officer.

Northeast Arc announced winners of the 2nd “The Arc Tank” competition created to positively disrupt conventional methods of providing services to persons with disabilities.

Biovation Labs, a leading supplement contract manufacturer, today announced it is expanding its capabilities to better serve its clients with the installation of an Aquarius G-J high speed rotary tablet press from Kikusui.

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointment of Dr Joseph D Khoury as a Scientific Advisor to the Company’s established Scientific Advisory Board.

Phenomix Sciences, an early stage Mayo Clinic startup company focused on personalizing chronic disease treatment, announced today it is opening up its seed round of financing to enable commercialization of a new clinical test for obesity.

UNC REX Healthcare plans to open a new Cancer Center across the street from its main Raleigh campus to meet the increasing need for oncology treatment and services, and serve patients from across Eastern North Carolina for generations to come.

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the BMO Prescriptions for Success Healthcare Conference

The Biotechnology Innovation Organization (BIO) today announced preliminary programing for the upcoming BIO CEO & Investor Conference to be held February 11-12, 2019 in New York City.

ObsEva SA (NASDAQ: OBSV / SIX: OBSN), today announced initiation of the IMPLANT 4 Phase 3 clinical trial of its oral oxytocin receptor antagonist, nolasiban, for the improvement of rates of pregnancy and live birth in patients undergoing assisted reproduction technology (ART), or in-vitro fertilization (IVF).